JP2019519529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519529A5 JP2019519529A5 JP2018561669A JP2018561669A JP2019519529A5 JP 2019519529 A5 JP2019519529 A5 JP 2019519529A5 JP 2018561669 A JP2018561669 A JP 2018561669A JP 2018561669 A JP2018561669 A JP 2018561669A JP 2019519529 A5 JP2019519529 A5 JP 2019519529A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- seq
- nos
- domain comprises
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 7
- 102000038129 antigens Human genes 0.000 claims 7
- 108091007172 antigens Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 238000003259 recombinant expression Methods 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000003834 intracellular Effects 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 102100008191 CD8A Human genes 0.000 claims 2
- 101700054655 CD8A Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 102100004573 FLT3 Human genes 0.000 claims 1
- 101710009074 FLT3 Proteins 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims 1
- 230000003449 preventive Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (16)
- ＦＬＴ３に特異的な抗原結合ドメイン、膜貫通ドメイン及び細胞内Ｔ細胞シグナル伝達ドメインを含むキメラ抗原受容体（ＣＡＲ）であって、
（ａ） 該抗原結合ドメインが、配列番号１３〜１９の配列を含む軽鎖可変領域を含むか；又は
（ｂ） 該抗原結合ドメインが、配列番号５〜１１の配列を含む重鎖可変領域を含む、
ＣＡＲ。 - 前記抗原結合ドメインが、配列番号１３〜１９の配列を含む軽鎖可変領域を含む、請求項１のＣＡＲ。
- 前記抗原結合ドメインが、配列番号５〜１１の配列を含む重鎖可変領域を含む、請求項１又は２のＣＡＲ。
- 前記抗原結合ドメインが配列番号１２のリンカー配列を含む、請求項１〜３のいずれか一項のＣＡＲ。
- 前記抗原結合ドメインが配列番号５〜１９を含む、請求項１〜４のいずれか一項のＣＡＲ。
- 前記膜貫通ドメインが、配列番号２５のＣＤ８αヒンジ配列及び配列番号２６の膜貫通ドメイン配列を含む、ＣＤ８アミノ酸配列を含む、請求項１〜５のいずれか一項のＣＡＲ。
- 前記細胞内Ｔ細胞シグナル伝達ドメインが、配列番号２７の４−１ＢＢのアミノ酸配列を含む、請求項１〜６のいずれか一項のＣＡＲ。
- 前記細胞内Ｔ細胞シグナル伝達ドメインが、配列番号２８のＣＤ３ゼータのアミノ酸配列を含む、請求項１〜７のいずれか一項のＣＡＲ。
- 前記ＣＡＲが、配列番号２１〜２４を含むスペーサーを更に含む、請求項１〜８のいずれか一項のＣＡＲ。
- 前記ＣＡＲが、配列番号１、２、２９又は３０の配列のいずれか1つを含む、請求項１のＣＡＲ。
- 請求項１〜１０のいずれか一項のＣＡＲをコードするヌクレオチド配列を含む、核酸。
- 請求項１１の核酸を含む、組換え発現ベクター。
- 請求項１２の組換え発現ベクターを含む、単離された宿主細胞。
- 請求項１〜１０のいずれか一項のＣＡＲ、請求項１１の核酸、請求項１２の組換え発現ベクター、請求項１３の宿主細胞又はその細胞集団と、医薬的に許容される担体とを含む、医薬組成物。
- 請求項１〜１０のいずれか一項のＣＡＲ、請求項１１の核酸、請求項１２の組換え発現ベクター、請求項１３の宿主細胞若しくはその細胞集団、又は請求項１４の医薬組成物を含む、哺乳動物における、がんの治療剤又は予防剤。
- 前記がんが、プレＢ細胞前駆体急性リンパ芽球性白血病又は急性骨髄性白血病である、請求項１５の剤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022089863A JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342394P | 2016-05-27 | 2016-05-27 | |
| US62/342,394 | 2016-05-27 | ||
| PCT/US2017/034691 WO2017205747A1 (en) | 2016-05-27 | 2017-05-26 | Flt3-specific chimeric antigen receptors and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089863A Division JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519529A JP2019519529A (ja) | 2019-07-11 |
| JP2019519529A5 true JP2019519529A5 (ja) | 2020-07-09 |
Family
ID=59054226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561669A Pending JP2019519529A (ja) | 2016-05-27 | 2017-05-26 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
| JP2022089863A Pending JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022089863A Pending JP2022130396A (ja) | 2016-05-27 | 2022-06-01 | Ｆｌｔ３特異的なキメラ抗原受容体及びそれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11299546B2 (ja) |
| EP (1) | EP3464366A1 (ja) |
| JP (2) | JP2019519529A (ja) |
| AU (1) | AU2017271606A1 (ja) |
| CA (1) | CA3025516A1 (ja) |
| WO (1) | WO2017205747A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3025516A1 (en) * | 2016-05-27 | 2017-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
| CA3073421A1 (en) | 2017-09-26 | 2019-04-04 | Daniel Mark COREY | Chimeric engulfment receptor molecules and methods of use |
| US20210253696A1 (en) * | 2020-01-21 | 2021-08-19 | Cero Therapeutics, Inc. | Bivalent chimeric engulfment receptors and uses thereof |
| EP4142749A1 (en) * | 2020-04-30 | 2023-03-08 | The Regents of the University of Colorado, A Body Corporate | Multispecific anti-flt3 chimeric antigen receptors |
| CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| EP3305798A1 (en) * | 2010-12-09 | 2018-04-11 | The Trustees of The University of Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG11201406414WA (en) | 2012-04-11 | 2014-11-27 | Us Health | Chimeric antigen receptors targeting b-cell maturation antigen |
| WO2014164544A1 (en) * | 2013-03-09 | 2014-10-09 | Baylor College Of Medicine | Vascular-targeted t-cell therapy |
| SG11201604565WA (en) | 2013-12-06 | 2016-07-28 | Us Health | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| KR102594343B1 (ko) * | 2014-07-21 | 2023-10-26 | 노파르티스 아게 | Cd33 키메라 항원 수용체를 사용한 암의 치료 |
| CA2967222C (en) * | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| KR20180053744A (ko) * | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
| US20190112380A1 (en) * | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US11768203B2 (en) * | 2016-03-31 | 2023-09-26 | University Of Southern California | Highly sensitive and specific luciferase based reporter assay for antigen detection |
| CA3025516A1 (en) * | 2016-05-27 | 2017-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
| EP4142749A1 (en) * | 2020-04-30 | 2023-03-08 | The Regents of the University of Colorado, A Body Corporate | Multispecific anti-flt3 chimeric antigen receptors |
-
2017
- 2017-05-26 CA CA3025516A patent/CA3025516A1/en active Pending
- 2017-05-26 WO PCT/US2017/034691 patent/WO2017205747A1/en unknown
- 2017-05-26 US US16/304,552 patent/US11299546B2/en active Active
- 2017-05-26 EP EP17729627.4A patent/EP3464366A1/en active Pending
- 2017-05-26 AU AU2017271606A patent/AU2017271606A1/en active Pending
- 2017-05-26 JP JP2018561669A patent/JP2019519529A/ja active Pending
-
2022
- 2022-03-08 US US17/689,698 patent/US20220259317A1/en active Pending
- 2022-06-01 JP JP2022089863A patent/JP2022130396A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519529A5 (ja) | ||
| JP2018531014A5 (ja) | ||
| EP4282877A3 (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2018029594A5 (ja) | ||
| JP2022109953A5 (ja) | ||
| JP2016502512A5 (ja) | ||
| JP2019506841A5 (ja) | ||
| JP2020517635A5 (ja) | ||
| JP2016538830A5 (ja) | ||
| JP2017513478A5 (ja) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2017537622A5 (ja) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2014534207A5 (ja) | ||
| JP2018064568A5 (ja) | ||
| JP2017526361A5 (ja) | ||
| JP2018529327A5 (ja) | ||
| JP2018505139A5 (ja) | ||
| JP2016520074A5 (ja) | ||
| JP2019530431A5 (ja) | ||
| JP2016532693A5 (ja) | ||
| JP2016539096A5 (ja) | ||
| JP2017528158A5 (ja) | ||
| JP2016527286A5 (ja) | ||
| JP2020501532A5 (ja) |